A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer

• Status: Completed
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study will compare the cancer response to both treatments for locally advanced or metastatic breast cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Collaborator: Genentech, Inc.
• Treatments: Albumin-Bound Paclitaxel; Bevacizumab; Gemcitabine; Paclitaxel

Criteria

Inclusion Criteria:

• Females diagnosed with breast cancer and the cancer has spread to distant areas of the breast or organs.

• Must be able to measure the disease by specific medical parameters

• May have received breast cancer treatment in the early stage of the disease

• May be restricted in physically strenuous activity but able to carry out light work.

• Must have adequate organ function as seen in blood test results.

Exclusion

Criteria:

• Cancer that has spread to the brain.

• Unstable heart problems

• Unstable high blood pressure.

• Breast cancer treatment after the disease has considered to spread to other areas or organs.

• Unable to agree with the requirements of the study